

Table. S2 Clinical characteristics of patients with Graves' disease (GD) and healthy control subjects (HC) for validation.

	GD	HC	p-Value
Number	24	24	-
male	45.800%	20.800%	0.125
Female	54.200%	79.200%	0.125
Age (years) ^a	40.920±12.628	38.630±11.813	0.519
FT3 (pmol/L) ^a	19.388±13.353	4.736±0.520	<0.001
FT4 (pmol/L) ^a	46.641±32.283	16.158±1.961	<0.001
TSH (mIU/L) ^a	0.701±3.406	1.724±0.896	<0.001
TRAb (IU/L) ^b	15.295(6.865-30.705)	0.800(0.800-0.800)	<0.001
TgAb (IU/L) ^b	55.580(20.963-383.425)	15.250(12.950-18.545)	<0.001
TPOAb (IU/L) ^b	173.560(15.843-383.068)	10.250(9.168-12.875)	<0.001

aVariables are expressed as mean ± standard deviation (SD); an unpaired independent sample t-test was used for comparisons between groups. **b**Variables are shown as median (IQR); a Non-parametric Mann–Whitney test was performed for comparisons between groups. *p* < 0.05 is considered to be statistically significant.

FT3 free T3, FT4 free T4, TRAb thyrotropin receptor antibodies, TPOAb, thyroperoxidase antibody, TgAb antithyroglobulin antibody.